Correction to: Vildagliptin Attenuates Huntington's Disease Through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model
Neurotherapeutics
.
2022 Mar;19(2):686.
doi: 10.1007/s13311-022-01227-6.
Authors
Noha H Sayed
1
,
Nevine Fathy
2
,
Mona A Kortam
1
,
Mostafa A Rabie
3
,
Ahmed F Mohamed
3
,
Ahmed S Kamel
3
Affiliations
1
Department of Biochemistry, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt.
2
Department of Biochemistry, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt. nevine.abdallah@pharma.cu.edu.eg.
3
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt.
PMID:
35352287
PMCID:
PMC9226260
DOI:
10.1007/s13311-022-01227-6
No abstract available
Publication types
Published Erratum